en · de · es · pt
compound-index.peptides6908.com › Data › Molecular Structure And Biological Background — Beginner to Advanced

Molecular Structure And Biological Background — Beginner to Advanced

By Editorial Desk · published 2025-12-03 · last reviewed 2026-01-20 · Data

This is a working overview of immune modulation, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-01-20 and is reviewed periodically as new material appears.

Molecular Structure and Biological Background

Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.

The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.

Identity and Molecular Background

The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.

Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.

Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Chemical classSynthetic peptide, 28 residuesN-terminal fragment of prothymosin alpha
Molecular massAbout 3108 DaAcetylated form
Isoelectric pointNear 4.2Acidic peptide
AppearanceWhite to off-white lyophilized powderCommon supplied form
Typical storage-20 °C or below, drySolution stability is lower

Background and Mechanism of Action

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

Related pages on this site

Stability, Storage, and Analysis

Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.

Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.

Reference notes

The IUPAC nomenclature (systematic way of naming compounds) for alkanes is based on identifying hydrocarbon chains. Unbranched, saturated hydrocarbon chains are named systematically with a Greek numerical prefix denoting the number of carbons and the suffix "-ane". In 1866, August Wilhelm von Hofmann suggested systematizing nomenclature by using the whole sequence of vowels a, e, i, o and u to create suffixes -ane, -ene, -ine (or -yne), -one, -une, for the hydrocarbons CnH2n+2, CnH2n, CnH2n−2, CnH2n−4, CnH2n−6. In modern nomenclature, the first three specifically name hydrocarbons with single, double and triple bonds; while "-one" now represents a ketone.

== Availability == Ketazolam is not approved for sale in Norway, Australia, United Kingdom or the United States. In South Africa, GlaxoSmithKline markets ketazolam under its Solatran brand name. In Canada, ketazolam is listed in schedule IV of the Controlled Drugs and Substances Act, along with other benzodiazepines.

== Sources and composition == Silk is not a single substance but a family of fibrous proteins spun by several different animals, and the silks used as biomaterials differ both in their origin and in the proteins they contain.

==== Thailand ==== In Thailand, Mister Donut has been a leader in the Thai donut market since 1978 and uses the slogan "Donut for Fun". As of December 2011, Thailand was the "largest market outside Japan for Mister Donut in terms of sales volume." Mister Donut has more than 320 branches across Thailand with more opening yearly. They include stand-alone stores as well as branches at shopping malls and supermarkets. In 2014, donut consumption increased 10 and 15 per cent in Thailand, with Mister Donut accounting for half of that increase. In 2015, Thailand's Central Restaurants Group announced plans to open 30 new outlets in 2015, bringing its store number to 350. The company stated that it would be able to sell "its doughnuts in all 77 provinces by year end." Central has also stated it is considering expanding Mister Donut in Malaysia, the Philippines, and Indonesia.

The International Brain Initiative was created in 2017, currently integrated by more than seven national-level brain research initiatives (US, Europe, Allen Institute, Japan, China, Australia, Canada, Korea, and Israel) spanning four continents.

Sources: en.wikipedia.org

Notes from published material

The gamma-emitting isotopes iodine-123 (half-life 13.223 hours), and (less commonly) the longer-lived and less energetic iodine-125 (half-life 59.392 days) are used as nuclear imaging tracers to evaluate the anatomic and physiologic function of the thyroid. Abnormal results may be caused by disorders such as Graves' disease or Hashimoto's thyroiditis. Both isotopes decay by electron capture (EC) to the corresponding tellurium nuclides, but in neither case are these the metastable nuclides 123mTe and 125mTe (which are of higher energy, and are not produced from radioiodine). Instead, the excited tellurium nuclides decay immediately (half-life too short to detect). Following EC, the excited 123Te from 123I emits a high-speed 127 keV internal conversion electron (not a beta ray) about 13% of the time, but this does little cellular damage due to the nuclide's short half-life and the relatively small fraction of such events. In the remainder of cases, a 159 keV gamma ray is emitted, which is well-suited for gamma imaging. Excited 125Te resulting from electron capture of 125I also emits a much lower-energy internal conversion electron (35.5 keV), which does relatively little damage due to its low energy, even though its emission is more common. The relatively low-energy gamma from 125I/125Te decay is poorly suited for imaging, but can still be seen, and this longer-lived isotope is necessary in tests that require several days of imaging, for example, fibrinogen scan imaging to detect blood clots.

There is evidence from both human and animal studies that inhalation exposure to ethylene oxide can result in a wide range of carcinogenic effects. Ethylene oxide is toxic by inhalation, with a US OSHA permissible exposure limit calculated as a TWA (time weighted average) over 8 hours of 1 ppm, and a short term exposure limit (excursion limit) calculated as a TWA over 15 minutes of 5 ppm. At concentrations in the air about 200 parts per million, ethylene oxide irritates mucous membranes of the nose and throat; higher contents cause damage to the trachea and bronchi, progressing into the partial collapse of the lungs. High concentrations can cause pulmonary edema and damage the cardiovascular system; the damaging effect of ethylene oxide may occur only after 72 hours after exposure. The maximum content of ethylene oxide in the air according to the US standards (ACGIH) is 1.8 mg/m3 (0.00079 gr/cu ft). NIOSH has determined that the Immediately Dangerous to Life and Health level (IDLH) is 800 ppm. Because the odor threshold for ethylene oxide varies between 250 and 700 ppm, the gas is already at toxic concentrations when it can be smelled. Even then, the odor of ethylene oxide is sweet and aromatic and can easily be mistaken for the aroma of diethyl ether, a common laboratory solvent of very low toxicity. In view of these insidious properties, continuous electrochemical monitoring is standard practice, and it is forbidden to use ethylene oxide to fumigate building interiors in the EU and some other jurisdictions.

== Background == In the process of evolution, from one generation to the next the amino acid sequences of an organism's proteins are gradually altered through the action of DNA mutations. For example, the sequence

Erythritol (, US: ) is an organic compound, the naturally occurring achiral meso four-carbon sugar alcohol (or polyol). It is the reduced form of either D- or L-erythrose and one of the two reduced forms of erythrulose. It is used as a food additive and sugar substitute. It is synthesized from corn using enzymes and fermentation. Its formula is C4H10O4, or HO(CH2)(CHOH)2(CH2)OH. Erythritol is 60–70% as sweet as table sugar. However, erythritol is almost completely noncaloric and does not affect blood sugar or cause tooth decay. Japanese companies pioneered the commercial development of erythritol as a sweetener in the 1990s.

Sources: en.wikipedia.org

Frequently asked questions

Is thymosin alpha-1 a naturally occurring hormone?

It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.

What is the difference between thymosin alpha-1 and other thymosins?

Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.

Does the peptide work by a single known mechanism?

No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.

What is thymosin alpha 1?

It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.

Network